Blockchain Registration Transaction Record

SureNano Science Advances Obesity Drug GEP-44 in $200B Market

SureNano Science (SURNF) advances GEP-44, a triple agonist peptide for obesity, in a $200B market. Differentiated with improved tolerability and delivery flexibility, it competes with Eli Lilly, Novo Nordisk.

This news matters because obesity and metabolic diseases affect millions worldwide, and current treatments often have tolerability and delivery issues. SureNano's GEP-44 could offer a more effective, better-tolerated alternative, potentially expanding patient access. As a microcap innovator, its success could disrupt the GLP-1 market dominated by big pharma, offering new options for patients and investment opportunities in a high-growth sector.